Peptides are of great interest to be used as vaccine antigens due to their safety, ease of manufacturing and specificity in generating immune response. There have been massive discoveries of peptide antigens over the past decade. However, peptides alone are poorly immunogenic, which demand co-administration with strong adjuvant to enhance their immunogenicity. Recently, fibril-forming peptides such as Q11 and lipoamino acid-based carrier have been identified to induce substantial immune responses when covalently linked to peptide epitope. In this study, we have incorporated either Q11 or lipoamino acids to a peptide epitope (J14) derived from M protein of Group A Streptococcus to develop selfadjuvanting vaccines. J14, Q11 and lipoamino acids were also conjugated together in a single vaccine construct in an attempt to evaluate the synergy effect of combining multiple adjuvants. Physicochemical characterization demonstrated that the vaccine constructs folded differently and self-assembled into nanoparticles. Significantly, only vaccine constructs containing double copies of lipoamino acids (regardless in conjugation with Q11 or not) were capable to induce significant dendritic cells uptake and subsequent J14-specific antibody responses in non-sizes dependent manners. Q11 had minimal impact in enhancing the immunogenicity of J14 even when it was used in combination with lipoamino acids. These findings highlight the impact of lipoamino acids moiety as a promising immunostimulant carrier and its number of attachment to peptide epitope was found to have a profound effect on the vaccine immunogenicity.
Self-adjuvanting vaccine against group

Introduction
Vaccine is the most successful medical intervention towards the control of many infectious diseases. The conventional vaccine commonly consists of inactivated pathogen or live attenuated pathogen. However, unwanted side effects such as allergies, autoimmune responses and inflammation are often associated with the use of conventional vaccines. 1, 2 In consequence, modern vaccine research has been shifted towards developing subunit vaccines which contain minimal microbial components that offer a safer alternative to the whole pathogens approach. Subunit vaccines are generally composed of one or multiple proteins derived from the pathogens. Instead of using whole proteins in vaccine formulation, it is possible to isolate individual epitopes within these proteins and develop peptide-based antigens. Peptides offer several advantages over proteins as they can be easily synthesized, purified and are eligible to elicit specific immune responses. 1, 3 However, peptides alone are weakly immunogenic and require co-administration with strong immunoadjuvants to induce the desired and robust immune responses. Vast amounts of adjuvants have been investigated to be used in mixture with peptide antigens, but majority of them failed to meet the safety requirement for clinical routine. This situation has necessitated the pursuit of self-adjuvanting vaccine which eliminates the use of external adjuvants that are potentially toxic. [4] [5] [6] Recently, it has been found that a short fibrillized peptide, Q11 (QQKFQFQFEQQ) covalently conjugated to peptide epitopes induced humoral and cellular immune responses. [7] [8] [9] The ovalbumin peptide 323-339 (OVA 323-339 )-Q11 conjugate raised antibody titers in a comparable level to the mixture of OVA 323-339 with complete Freund's adjuvant (CFA) in mice. 7 It was hypothesized that the Q11 peptide self-assembled into fibrillar network with the capability to display the OVA epitope on its surface in a repetitive manner ( Figure 1A) . It was also established that Q11 was not immunogenic on its own, thus would be suitable to be used for self-adjuvanting vaccine delivery system. Another strategy towards the development of self-adjuvanting vaccine is the conjugation of immunostimulatory lipids to peptide antigens. Lipidation of antigenic peptide with synthetic lipids such as lipoamino acids (LAAs) has been widely studied ( Figure 1B) . [10] [11] [12] Previous data suggested that LAAs with 16 carbon atoms (C16) were optimal for inducing strong humoral immunity that biased towards Th2 response (with predominant IgG1 production), once conjugated to B cell peptide epitopes. 4, 10, 13, 14 It has been recognized that LAAs may induce the activation of antigen presenting cells (APCs) by acting as a toll-like receptor-2 (TLR2) agonist. In present work, we have evaluated the applicability of Q11 and LAAs C16 as an adjuvanting moiety to a model antigen named J14. J14 is a 29-mer chimeric peptide, KQAEDKVKASREAKKQVEKALEQLEDKVK which contains a B cell epitope (highlighted in bold) derived from the M-protein conserved region of Group A Streptococcus (GAS). 17 The 14 amino acid GAS M-protein sequence is enclosed within alpha-helix promoter sequence to preserve its native conformation which is required to induce an antigen-specific humoral response. The discovery of J14 has been driven by the fact that antibodies against whole M-protein have the ability to cross-react with human tissues which resulted in autoimmune disease. 18 J14 eliminate the unwanted cross-reactivity consequence of M-protein, thus represent an ideal model for the needs of peptide-based subunit vaccine.
Antibodies elicited by J14 were capable to confer protection against broad spectrum of GAS serotypes only when delivered with strong adjuvants (e.g CFA) or bound to appropriate delivery platform. 19, 20 Currently, many efforts have been made towards the development of vaccine delivery systems that utilizes J14 as a major protective epitope. [21] [22] [23] Herein, several potentially self-adjuvanting vaccine candidates incorporating J14 conjugation to Q11 or LAAs C16 (either single or double copies) have been synthesized (Figure 2) . It has been postulated that incorporation of two or more self-adjuvanting moieties may produce a greater immunogenicity effect of the vaccine antigen than any single moiety. [24] [25] [26] Thus, J14
has also been conjugated to both Q11 and single/double C16 moiety in an attempt to evaluate the synergy effect of combining multiple adjuvants in a single vaccine construct. Vaccine constructs have been characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM) and circular dichroism (CD) spectroscopy. The ability of the vaccine candidates to induce uptake by professional APCs such as dendritic cells (DCs) and macrophages were also investigated. Finally, vaccine candidates were administered subcutaneously in B10.BR mice to evaluate their capabilities in inducing the systemic J14-specific IgG antibody production by using prime-boost immunization regimen. 
Results
Synthesis and physicochemical characterization of vaccine constructs
Each peptide-based vaccine constructs (1-5, Figure 3 ) was synthesized on pmethylbenzhydrylamine (pMBHA) resin by using stepwise solid-phase peptide synthesis via tert-butoxycarbonyl (Boc) chemistry. 27 The N-terminal of the peptide constructs was acetylated. A hydrophilic spacer Ser-Gly-Ser-Gly was inserted between the J14 and Q11 domains, with the J14 domain positioned at N-terminus to provide structural similarity to the reported work based on ligand-bearing Q11 derivatives. 7, 8 Likewise, Ser-Ser residues were included between the peptide domain and two lipidic moieties C16 as previously reported. [28] [29] [30] All of the compounds were successfully synthesized with purity greater than 95% after purification by RP-HPLC.
Most B cell peptide epitopes are required to adopt similar folded conformations of their native protein for efficient presentation to B cells. In regard to this prerequisite, the secondary structure of the vaccine constructs has been investigated. The circular dichroism (CD)
analysis was performed immediately after dissolving the compounds (day 0) and after two days incubation period (day 2) (Figure 3) . CD spectra of Q11 alone displayed a minimum peak at 228-230 nm, an indicatory to β-sheet or β-turn conformation. The spectrum data was consistent with the spectra of Q11 and its derivatives that have been previously reported.
7,31
The Q11 peptide possessed higher degree of β-sheet/β-turn structure in day 2 compared to day 0. This suggests that the arrangement of Q11 peptide into a β-sheet rich fibrillar network was time-dependent. However, there were no difference observed in terms of the spectra obtained for the vaccine constructs 1-5 in day 0 and day 2. Spectra of construct 3 (J14-Q11) suggested rather random coils than β-sheet structure which characterized by a minimum peak at 204 nm. Constructs 4 and 5 which contained J14 conjugated to lipid moieties (either single or double copies of C16) possessed a helix structure (negative bands at 208 nm and 222 nm).
This data demonstrated that the conjugation of lipid moieties to J14 induced α-helical conformation. Vaccine constructs 1 and 2 that possess both fibrilizing peptide and LAAs C16 moiety was expected to adopt a mixture of helical and β-sheet/β-turn secondary structure.
However, these compounds have higher propensity towards helical conformation with a shallow minimum peaks around 208nm and 222nm. The helical structure attained by vaccine constructs 1, 2, 4 and 5 is at a comparable degree to that previously reported with other selfadjuvanting delivery system for peptide-based GAS vaccines.
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Figure 3. CD spectra of vaccine constructs 1-5 and Q11 that analyzed immediately after formulation in PBS (A) and after 2 days incubation in PBS.
Size of vaccine particle has a significant influence on its uptake by APCs and contributes to the type or magnitude of the immune responses. 2, 24 The size of the vaccine constructs 1-5 in aqueous media was analyzed by dynamic light scattering (DLS) and transmission electron microscopy (TEM, Figure 4 ). Size analysis of the individual vaccine constructs was summarized in Table 1 . TEM showed that vaccine constructs 1-5 formed particles in aqueous solution (Fig. 4) . The diameter range of the particles was consistent with the size measured by DLS ( Table 1 
Uptake of vaccine constructs by dendritic cells and microphages
Uptake of the vaccine constructs 1-5 by dendritic cells (DCs) and macrophages was determined by incubating murine splenocytes with fluorescent dyes (dil)-labelled compounds.
The resultant cells-associated fluorescence was measured by flow cytometry. Overall, uptake of the vaccine constructs 1-5 was biased towards DCs than macrophages (Fig. 5) . Vaccine constructs 1 and 4 were shown to induce a significant uptake by DCs (Fig. 5A) . Otherwise, vaccine constructs 2, 3 and 5 failed to be taken up efficiently by DCs as there was no significant difference in uptake compared to PBS. Similar to DCs, macrophages were able to uptake only vaccine constructs 1 and 4 in an efficient manner. This data demonstrates that vaccine constructs containing double copies of LAAs C16 were capable to be taken up efficiently by the APCs with a favour towards dendritic cells than macrophages. Clearly, a single copy of C16 was insufficient to mediate uptake by either DCs or macrophages ( 
Evaluation of antibody response to vaccine constructs
Immunological evaluation of vaccine constructs 1-5 was executed in B10.BR mice by using a prime-boost vaccination strategy. The positive control group of mice was immunized with J14 emulsified in complete Freund's adjuvant (CFA), whereas the negative control was treated with PBS. Serum was collected 9 days after the final boost. Additional group of mice were injected with Q11/CFA mixture. There were no IgG levels raised against J14 detected in sera from this group, indicated that Q11 was not cross-reacted with J14. Among the vaccine constructs, 1 and 4 elicited a significant level of J14-specific IgG titers (Fig. 6) . The levels of IgG titers induced by these constructs were comparable to mice immunized with J14/CFA emulsification (p > 0.05). Vaccine construct 1 was comprised of J14, Q11 and two copies of LAAs C16 while construct 4 was consisted of J14 conjugated to double copies of C16. Even though higher IgG titers were observed for vaccine construct 1 in comparison to 4, the difference was not statistical significant. These data suggested that the combination strategy between Q11 and lipidic moieties (C16) as built-in immunoadjuvant has minimal effect in inducing antibody productions.
Constructs 2, 3 and 5 were unable to induce significant level of IgG productions (Fig. 6) .
Numbers of lipid attachments contribute significantly to the J14-specific IgG productions ( Fig. 6 ; vaccine construct 1 vs 2, p < 0.001). Similarly, compound 5 that have one C16 less than compound 4 were found to be ineffective in eliciting IgG response. Taken together, these data suggested that minimally two copies of C16 were required to induce significant Statistical analysis was performed using one-way ANOVA followed by Turkey post hoc test between groups as indicated (ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001).
Discussions
Lipid moieties conjugated to antigenic peptide have been used extensively to generate substantial immune responses without the need of external adjuvants. 35 The synthesis of lipid moieties are usually complex and its conjugation to peptide are often difficult to perform.
Lipid moieties based on LAAs can overcome these restrictions. LAAs represent structurally unique molecules, as they are synthetics amino acids featuring alkyl side-chain. 36 This nature enables them to be incorporated easily to any known peptide epitope via conventional peptide-coupling procedure, such as solid-phase peptide synthesis. The length of alkyl sidechain can be modified to enhance peptide immunogenicity. Recently, attachment of the short self-assembling amino acids sequence namely Q11 to a peptide epitope's C terminus was found to be successful in inducing significant immune responses. 7, 8, 37 Herein, fibril-forming peptide (Q11) and LAAs C16 have been evaluated for their application to be used as built-in adjuvants towards the development of self-adjuvanting vaccine against GAS (Fig. 2) . The potential synergy effects from the conjugation of Q11 and LAAs C16 in single construct have also been investigated. Vaccine candidates incorporating J14 conjugated to Q11 and/or LAAs C16 (single/double copies) created short polypeptides that were easily synthesized on a resin via conventional Boc-SPPS protocol.
Conjugation of lipid moieties to peptides (lipopeptides) prompts particle formation in aqueous environment. 23, 33 Similarly, vaccine constructs (1, 2, 4 and 5) encompassed of LAAs C16 (single/double copies) formed nanoparticles as determined by DLS and TEM ( Table 1) .
Extreme particles size distribution of vaccine constructs 3 and 4 were illustrated in TEM images where their size ranging from 20 nm -300 nm. Self-assembly of lipopeptides into particles may exhibit pathogen-like property by allowing antigens presentation in a multivalent format which may increase the chance of being recognized by APCs. Constructs with double copies of LAAs C16 (construct 4) have the tendencies to form larger particles than construct containing single copy of C16 (construct 5). This observation can be explained by the higher lipophilicity characteristic exhibited by constructs possessing two LAAs.
Lipopeptides with greater hydrophobicity may increase their propensity to self-assemble into larger particles as previously observed. 33 However, constructs 1 and 2 bearing Q11 and double or single copy of LAAs C16, respectively, formed small nanoparticles indicating significant influence of Q11 peptide on the constructs morphology. The stimulation of immune response is initiated by the uptake of the vaccine antigens by APCs. The size of the vaccine particle has great influence in its mechanism of uptake. Large vaccine particles (> 0.5 µm) are predominantly captured by macrophages while smaller particles (20-100 nm) are generally taken up by DCs. 24, 38 Consistently, the synthesized vaccine constructs were primarily taken up by DCs than macrophages (Fig. 5) . This was largely due to their particle size that falls within 10-300 nm as determined by DLS and TEM ( Table 1) . Our result suggests that at least double copies of LAAs C16 were required to induce optimal DCs uptake. Multiple copies of LAAs-based adjuvanting moiety in Lipid Core Peptide (LCP) technology were found to induce the activation of toll-like receptors 2 (TLR2). 30, 39 This explains the significant uptake of vaccine constructs 1 and 4 by dendritic cells that possess double copies of LAAs C16 as adjuvanting constituents. Therefore, targeting dendritic cells through toll-like receptor represents a feasible option for enhancing antigen uptake by these cells.
Immunization with vaccine construct 3 that comprised of J14-Q11 conjugation failed to induce significant titers of IgG. The present data was inconsistent with the previous report that utilized Q11 as immune adjuvant. This outcome can be explained by the different dosage used for immunization. In this work, mice immunized with J14-Q11 received a 10 times lower dose concentration than the previously reported immunization with Q11 conjugation to either OVA or malaria peptide antigen (NANP) 3 . 7, 8 The concentration used in present study was similar to that previously reported for other peptide-based vaccine evaluation in vivo that utilized J14 as antigen. 21, 23, 40 Unlike the OVA-Q11 and (NANP) 3 -Q11 conjugates, J14-Q11 was incapable to induce visible β-sheet conformation and unable to form a dense fibrillar network as observed by CD spectroscopy (Fig. 3) and TEM (Fig. 4C) respectively. The disruption of fibril formation could also lead to the loss of adjuvanting activity of Q11. It has been recognized that peptide fibrillization may improve the peptide stability against enzymatic degradation, which would provide a 'depot effect' that elongates the residence time of peptide antigen at the injection site for efficient uptake by dendritic cells. In addition, epitope fibrillization may also facilitate phagocytosis and stimulation of antigen presenting cells. Apparently, the synthesized J14-Q11 conjugate predominantly self-assembled into nanoparticles as determined by TEM. Thus, these suggest that fibrillized peptide such as Q11
is not a generic adjuvant system for peptide-based antigen. On the whole, the fibrillar platform-based adjuvant has a minimal dose-sparing effect as high dose was required to exhibit its immunogenicity effect.
In 
Conclusion
In this study, the synthesis, characterization and immunological evaluation of selfadjuvanting vaccine constructs against GAS that utilized fibrillized peptide (Q11) and lipidic moiety (C16) as built-in immunoadjuvants have been reported. Lipidation of the antigenic peptide (J14) with double copies of LAAs C16 were found to be the minimal requirement to stimulate substantial antibody titers in mice. Moreover, two copies of LAAs C16 have been demonstrated to be essential in inducing the uptake by DCs. At similar dosage, Q11 was incapable to induce immune response against J14 B cell epitope or in enhancing vaccine immunogenicity when it was used in combination with two copies of LAAs C16 as adjuvanting constituent. However, the immune responses elicited were not dependent on the size of the vaccine constructs. Taken together, these findings provide insights towards the development of self-adjuvanting vaccine based on LAAs C16 as built-in immunoadjuvant.
The constructed vaccine candidates are relatively easy to produce, well chemically defined and cost-effective in terms of commercial perspective which makes them more valuable for further research to satisfy clinical application.
Materials and method
Materials
Protected L-amino acids and pMBHA resin were purchased from Novabiochem 10µm, 22 × 250 mm). CD spectra were measured by using a JASCO J-710 spectropolarimeter. Sizes were analyzed via a Zetasizer Nano ZP instrument (Malvern Instrument, UK) via DTS software. Transmission electron microscopy was performed using a JEM-1010 transmission electron microscopy (JEOL Ltd, Japan) operated at 100 kV.TEM images were analysed using the Analysis® software (Soft Imaging Systems, Megaview III, Munster, Germany).
Peptide synthesis and purification
Each vaccine constructs (1-5, Fig. 1 
Circular Dichroism (CD) Spectroscopy
CD spectra were measured on a quartz cuvette with a 1mm path length at 23 °C. CD spectra analysis data were collected between 198 nm and 260 nm. Compounds (vaccine constructs 1-5 and Q11) were analysed as freshly dissolved in PBS and after incubation at 4 °C for 2 days. Measurements were performed in triplicate with the average subtracted from the blank PBS solution. The mean residual ellipticity was calculated as published elsewhere. 12 Working concentration for each compounds were based on concentration used for animal studies (0.6 µg/µL).
Dynamic Light Scattering (DLS)
Sizes were analyzed using a non-invasive back scatter system via dynamic light scattering technique. Measurements were taken at 25 °C with scattering angle of 173° by disposable cuvettes. Particles of the synthesized compounds were preparedin PBS based on concentration used in animal studies (0.6 µg/µL). The measurements were conducted at least three times.
Transmission Electron Microscopy (TEM)
Compounds were dissolved in deionized water to produce working concentrations based on in vivo studies. After 2 days of incubation period, compounds were applied to carbon coated 200 mesh grids and negative-stained with 1% uranyl acetate. Images were taken from a JEM-1010 transmission electron microscope (JEOL Ltd., Japan) operated at 80 kV. 
Uptake of Vaccine
Collection of sera
Blood was collected from the tail artery of each mouse 1 day prior to each injection and 9 days after the last immunizations. The blood was left to clot at 37 °C for 1 hr and then centrifuged for 10 minutes at 3000 rpm to remove clots. Sera were then stored at -20 °C.
ELISA for Systemic IgG Antibodies Detection
Detection of serum IgG antibodies against the J14 epitope was performed using an enzyme linked immunosorbent assay (ELISA) as previously reported. 41 Briefly, ELISA plates were coated with J14 (10 mg/ml) in carbonate coating buffer overnight at 4 °C and blocked with 150 µL/well of 5% skim milk for 90 minutes at 37 °C. Serial dilutions of collected sera were prepared in 0.5% skim milk /PBS-Tween-20 buffer, starting at 1:100 concentration followed by 1:2 dilutions. Absorbance values were read at 450 nm in a microplate reader after the addition of secondary antibody (peroxidise-conjugated antimouse IgG) and Ophenylenediamine. The antibody titer was identified as the lowest dilution that give absorbance of more than 3 standard deviations above the mean absorbance of control wells (contains normal mouse serum). Statistical analysis (p < 0.05 = statistical significance) was performed with one-way ANOVA followed by Turkey post hoc test.
